AI Reads Cancer Biopsies to Match Myeloma Patients to Care

Doctors treating multiple myeloma now have a powerful new ally in deciding which therapies will work best for each patient.

Researchers at the University of Miami's Sylvester Comprehensive Cancer Center have developed an AI system that reads standard bone marrow biopsy slides to reveal hidden patterns in a patient's immune system. Those patterns help predict who will respond best to specific treatments.

The technology addresses a critical challenge in cancer care. Multiple myeloma patients often respond very differently to the same therapies, but doctors have struggled to predict those outcomes in advance.

Research scientist Arjun Raj Rajanna and his team trained their AI model, called GigaTIME, to spot immune signals that human eyes miss. They tested it on 212 newly diagnosed patients from the HealthTree Foundation registry.

The results were striking. Patients with low levels of a specific immune marker benefited dramatically when they received the immunotherapy drug daratumumab alongside standard treatment. At 18 months, 86.8% of these patients remained event-free compared to just 28.6% who received standard treatment alone.

The AI also revealed something equally important. Patients with high levels of the immune marker did just as well without stem cell transplants, a grueling procedure that can weaken the immune system and increase infection risk.

"We are using AI to move toward a more precision-based treatment approach," Rajanna explained. "Instead of asking which drug combination is best overall, we are asking which treatment strategy best fits the biology of each individual patient."

Dr. C. Ola Landgren, director of the Sylvester Myeloma Institute, emphasized that the findings don't eliminate the need for transplants. Instead, they suggest that transplant decisions can become more personalized and driven by each patient's unique biology.

The breakthrough is especially meaningful because it works with routine biopsy slides that doctors already collect. No special tests or expensive new procedures are required.

Why This Inspires

This research represents medicine moving in exactly the right direction. For decades, cancer patients have endured one-size-fits-all approaches that leave some undertreated and others facing unnecessary side effects.

Now, artificial intelligence is helping doctors see what was always there but invisible to the human eye. The same slides pathologists have examined for years are revealing secrets about each patient's immune landscape.

The implications extend beyond multiple myeloma. If AI can unlock personalized insights from standard biopsies for one cancer, the same approach could transform treatment decisions across oncology.

For patients newly diagnosed with multiple myeloma, this technology offers something precious: the possibility of getting the right treatment intensity from the start, avoiding both under-treatment and over-treatment.

The team presented their findings at the 2026 American Society of Clinical Oncology Annual Meeting, marking what Dr. Landgren calls "the beginning of a new era of AI-enabled digital pathology in myeloma."

Better outcomes with fewer side effects is the promise of precision medicine finally becoming real.